(ESPR)
NGM – Real Time Price. Currency in USD
2.74
-0.11 (-3.86%)
At close: Mar 27, 2026, 4:00 PM EDT
2.72
-0.02 (-0.73%)
After-hours: Mar 27, 2026, 5:54 PM EDT
Get all premium features to the best stock analysis tool
NGM – Real Time Price. Currency in USD
2.74
-0.11 (-3.86%)
At close: Mar 27, 2026, 4:00 PM EDT
2.72
-0.02 (-0.73%)
After-hours: Mar 27, 2026, 5:54 PM EDT
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
| Name | Position |
|---|---|
| Dr. Stephen Pinkosky | Vice President of Drug Discovery of Early Pre-Clinical Development |
| LeAnne Bloedon M.S. | VP & Head of Development |
| Mr. Benjamin Halladay M.B.A. | Chief Financial Officer |
| Mr. Benjamin O. Looker J.D. | General Counsel & Corporate Secretary |
| Mr. Glenn P. Brame | Chief Technical Operations Officer |
| Mr. John B. Harlow Jr. | Chief Commercial Officer |
| Mr. Sheldon L. Koenig M.B.A. | President, CEO & Director |
| Date | Type | Document |
|---|---|---|
| 2026-03-10 | 10-K | espr-20251231.htm |
| 2026-03-03 | 8-K | espr-20260302.htm |
| 2026-01-12 | 8-K | espr-20260111.htm |
| 2025-11-06 | 10-Q | espr-20250930.htm |
| 2025-11-04 | 8-K | espr-20251104.htm |
| 2025-10-08 | 8-K | tm2527818d4_8k.htm |
| 2025-10-07 | 8-K | tm2527818d2_8k.htm |
| 2025-08-13 | S-8 | esprs-882025.htm |
| 2025-08-11 | NT 10-Q | espr06302025nt10-q.htm |
| 2025-08-05 | 8-K | espr-20250805.htm |
| Ms. Betty Jean Swartz |
| Chief Business Officer |
| Tiffany Aldrich M.B.A. | Associate Director of Corporate Communications |